Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography yumor density, choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma

European Urology

Volumn 59, Issue 5, 2011, Pages 856-862

  Krajewski, Katherine M ^a   Guo, Mengye ^a   Van Den Abbeele, Annick D ^a   Yap, Jeffrey ^a   Ramaiya, Nikhil ^a   Jagannathan, Jyothi ^a   Heng, Daniel Y C ^b   Atkins, Michael B ^c   McDermott, David F ^c   Schutz, Fabio A B ^d   Pedrosa, Ivan ^c   Choueiri, Toni K ^d,e  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b TOM BAKER CANCER CENTRE   (Canada)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e NONE   (United States)

Author keywords

Choi; RECIST 1.0; Renal cell carcinoma; Tumor shrinkage; VEGF targeted therapy

Indexed keywords

BEVACIZUMAB; SORAFENIB; SUNITINIB;

ADULT; ARTICLE; CANCER SURVIVAL; COMPUTED TOMOGRAPHY SCANNER; EARLY POSTHERAPY IMAHGING CHANGES; EVALUATION; HUMAN; IMAGING SYSTEM; INTERMETHOD COMPARISON; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RESPONSE EVALUATION CRITERIA IN SOLID TUMOR; TREATMENT FAILURE;

ACADEMIC MEDICAL CENTERS; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; BENZENESULFONATES; BOSTON; CARCINOMA, RENAL CELL; HUMANS; INDOLES; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; OBSERVER VARIATION; PREDICTIVE VALUE OF TESTS; PYRIDINES; PYRROLES; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; ROC CURVE; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79953247379     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2011.01.038     Document Type: Article

References (18)

1. A. Baccala, R. Hedfepeth, J. Kaouk, Magi-Galluzi, T. Gilligan, and A. Fergany Pathological evidence of necrosis in recurrent renal mass following treatment with sunitinib Int J Urol 14 2007 1095 1097 (Pubitemid 350151265)
2. C.L. Cowey, J.R. Fielding, and W.K. Rathmell The loss of radiographic enhancement in primary renal cell carcinoma tumors following multitargeted receptor tyrosine kinase therapy is an additional indicator of response Urol 75 2010 1108 1113
3. J.C. Yang, L. Haworth, and R.M. Sherry A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cell carcinoma N Engl J Med 349 2003 427 434 (Pubitemid 36910021)
4. R.J. Motzer, T.E. Hutson, and P. Tomczak Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2007 115 124 (Pubitemid 46089672)
5. B. Escudier, T. Eisen, and W.M. Stadler Sorafenib in advanced renal cell carcinoma N Engl J Med 356 2007 125 134 (Pubitemid 46089673)
6. R.J. Motzer, M.D. Michaelson, and J. Rosenberg Sunitinib efficacy against advanced renal cell carcinoma J Urol 178 2007 1883 1887 (Pubitemid 47538608)
7. R.S. Benjamin, H. Choi, and H.A. Macapinlac We should desist using RECIST, at least in GIST J Clin Oncol 25 2007 1760 1764 (Pubitemid 46797958)
8. H. Choi, C. Charnsangavej, and S.C. Faria Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria J Clin Oncol 25 2007 1753 1759 (Pubitemid 46797957)
9. A.A.M. Van der Veldt, M.R. Meijerink, A.J.M. van den Eertwegh, J.B.A.G. Haanen, and E. Boven Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell carcinoma treated with sunitinib Br J Cancer 102 2010 803 809
10. A.D. Smith, M.L. Leiber, and S.N. Shah Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT AJR 194 2010 157 165
11. A.D. Smith, S.N. Shah, B.I. Rini, M.L. Lieber, and E.M. Remer Morphology, attenuation, size and structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy AJR 194 2010 1470 1478
12. R. Thiam, L.S. Fournier, and L. Trinquart Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib Ann Oncol 21 2010 936 941
13. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
14. E.L. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Amer Statist Assn 53 1958 457 481
15. P.D. Nathan, A. Vinayan, and D. Stott CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies Cancer Biol Ther 9 2010 15 19
16. K.S. Han, D.C. Jung, and J.F. Choi Pretreatment assessment of tumor enhancement on contrast-enhanced computed tomography as a potential predictor of treatment outcome in metastatic renal cell carcinoma patients receiving antiangiogenic therapy Cancer 116 2010 2332 2342
17. L.S. Fournier, S. Oudard, and R. Thiam Metastatic renal carcinoma: evaluation of antiangiogenic therapy with dynamic contrast-enhanced CT Radiology 256 2010 511 518
18. C. De Bazelaire, D.C. Alsop, and D. George MRI measured tumor blood flow change following antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in patients with metastatic renal cell carcinoma Clin Cancer Res 14 2008 5548 5554